Aptevo Therapeutics Q3 net loss widens to $7.5 mln

Aptevo Therapeutics

06/11/2025 13:13

Overview

Aptevo Q3 net loss widens to $7.5 mln, driven by increased R&D and admin expenses

Company raises $22.8 mln since Q2 end, extending cash runway into Q4 2026

Introduces trispecific molecules APVO451 and APVO452, expanding oncology portfolio

Outlook

Company extends cash runway into 4Q26 with recent capital raises

Aptevo introduces trispecific molecules APVO451 and APVO452 for solid tumors

Company focuses on expanding CD3 T-cell engager portfolio to five molecules

Result Drivers

R&D - Q3 net loss widens to $7.5 mln, driven by increased R&D and admin expenses

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
-$2.23
Q3 Net Income
-$7.55 mln
Q3 Operating Income
-$7.61 mln


Analyst Coverage

The one available analyst rating on the shares is "buy"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Aptevo Therapeutics Inc is $420.00, about 99.7% above its November 5 closing price of $1.43

Press Release: ID:nACSdQRTLa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)